Literature DB >> 2044083

Serum soluble interleukin-2 (IL-2) receptor levels in women with breast carcinoma and its correlation with IL-2 receptor expression on blood lymphocytes and lymphocytic infiltration within the tumour.

S Sharma1, K Saha, R N Shinghal, G B Malik.   

Abstract

This study describes serum levels of soluble interleukin-2 receptor (sIL-2R) in 13 healthy women, 10 women with breast dysplasia and 37 patients with breast carcinoma. A difference was found between sIL-2R levels in normal women and cancer patients. sIL-2R increased with the advance in stage of cancer but the extent of increase fell from stage III to stage IV as compared to the change from stage II to stage III. Of the 15 patients who were followed after surgery and/or therapy, 10 (67%) showed a fall in the serum sIL-2R levels. A negative correlation was found between sIL-2R levels and lymphocytic infiltration only within the malignant tissue. These findings probably indicate that sIL-2R exerts an immunomodulatory effect on blood lymphocytes by preventing their infiltration into the tumour tissue. To our knowledge, this is the first report of its kind in immunology of breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044083     DOI: 10.1007/bf01756142

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Elevated serum levels of soluble interleukin 2 receptors in HIV infection: correlation studies with markers of cell activation.

Authors:  J M Lang; G Coumaros; S Levy; A Falkenrodt; M Steckmeyer; M Partisani; A Aleksijevic; L Lehr; C Koehl
Journal:  Immunol Lett       Date:  1988-10       Impact factor: 3.685

2.  Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes.

Authors:  D M Komp; J McNamara; P Buckley
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

3.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

Authors:  T Uchiyama; D L Nelson; T A Fleisher; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  Immunologic tools to decipher efficacy of BCG immunotherapy in advanced breast cancer: a one year follow up study.

Authors:  K Saha; H Kapila; R Madan; R N Shinghal
Journal:  Asian Pac J Allergy Immunol       Date:  1986-12       Impact factor: 2.310

5.  Quantitation of lymphocytes and T-cell subsets in patients with disseminated cancer.

Authors:  M A Cobleigh; D P Braun; J E Harris
Journal:  J Natl Cancer Inst       Date:  1980-05       Impact factor: 13.506

6.  Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease.

Authors:  N Yasuda; P K Lai; S H Ip; P C Kung; Y Hinuma; M Matsuoka; T Hattori; K Takatsuki; D T Purtilo
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

7.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

8.  Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia.

Authors:  C H Pui; S H Ip; S Iflah; F G Behm; B H Grose; R K Dodge; W M Crist; W L Furman; S B Murphy; G K Rivera
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

9.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  9 in total

1.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

2.  Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.

Authors:  E Paietta; D L Nelson; J Andersen; J P Dutcher; P H Wiernik
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

3.  Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.

Authors:  N El Houda Agueznay; C Badoual; S Hans; A Gey; B Vingert; S Peyrard; F Quintin-Colonna; P Ravel; P Bruneval; S Roncelin; B Lelongt; J Bertoglio; W H Fridman; D Brasnu; E Tartour
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

4.  Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.

Authors:  Liang Wang; Ding-zhun Liao; Jing Zhang; Zhong-jun Xia; Xiong-wen Peng; Yue Lu
Journal:  Med Oncol       Date:  2013-09-15       Impact factor: 3.064

5.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

6.  Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.

Authors:  S Mariotti; G Barbesino; P Caturegli; M Marinò; L Manetti; L Fugazzola; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

7.  Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.

Authors:  B Nakata; K H Chung; Y Kato; Y Yamashita; A Inui; Y Arimoto; K Maeda; N Onoda; T Sawada; M Sowa
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

Review 8.  On the role of sIL-2R measurements in rheumatoid arthritis and cancers.

Authors:  Anna Maria Witkowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

9.  Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.

Authors:  R Gooding; P Riches; G Dadian; J Moore; M Gore
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.